Bone Debt Equity Ratio from 2010 to 2024

BBLGW Stock  USD 27.80  0.00  0.00%   
Bone Biologics Debt Equity Ratio yearly trend continues to be fairly stable with very little volatility. Debt Equity Ratio will likely drop to -0.81 in 2024. During the period from 2010 to 2024, Bone Biologics Debt Equity Ratio regression line of quarterly data had r-squared of  0.06 and coefficient of variation of (39.78). View All Fundamentals
 
Debt Equity Ratio  
First Reported
2010-12-31
Previous Quarter
(0.77)
Current Value
(0.81)
Quarterly Volatility
0.4030693
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Debt Equity Ratio Growth Pattern

Below is the plot of the Debt Equity Ratio of Bone Biologics Corp over the last few years. It is Bone Biologics' Debt Equity Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Debt Equity Ratio10 Years Trend
Pretty Stable
   Debt Equity Ratio   
       Timeline  

Bone Debt Equity Ratio Regression Statistics

Arithmetic Mean(1.01)
Coefficient Of Variation(39.78)
Mean Deviation0.26
Median(0.86)
Standard Deviation0.40
Sample Variance0.16
Range1.2388
R-Value0.25
Mean Square Error0.16
R-Squared0.06
Significance0.36
Slope0.02
Total Sum of Squares2.27

Bone Debt Equity Ratio History

2024 -0.81
2023 -0.77
2020 -0.86
2019 -0.95
2018 -1.05
2017 -0.98
2016 -1.01

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Debt Equity Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt Equity Ratio(0.77)(0.81)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.